Jubilant Pharmova’s subsidiary company -- Jubilant Pharma has successfully completed studies using a novel oral formulation of Remdesivir used for treatment of COVID-19 against the available injectable formulation of the antiviral drug in India. Jubilant has sought authorization for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI). Jubilant is hoping to provide an affordable, more convenient, easy-to-administer and potentially effective treatment option for COVID-19 patients.
The proposed oral treatment is expected to be for 5 days, duration similar to the injectable dosage form. Remdesivir is the first and the only anti-viral drug fully approved by the USFDA for the treatment of patients with COVID-19 requiring hospitalization.
Jubilant Pharmova (formerly Jubilant Life Sciences Limited) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
